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Abstract
Background: Accurate prognostication of locally advanced nasopharyngeal carcinoma (NPC) will benefit patients for
tailored therapy. Here, we addressed this issue by developing a mathematical algorithm based on support vector machine
(SVM) through integrating the expression levels of multi-biomarkers.
Methodology/Principal Findings: Ninety-seven locally advanced NPC patients in a randomized controlled trial (RCT),
consisting of 48 cases serving as training set and 49 cases as testing set of SVM models, with 5-year follow-up were studied.
We designed SVM models by selecting the variables from 38 tissue molecular biomarkers, which represent 6 tumorigenesis
signaling pathways, and 3 EBV-related serological biomarkers. We designed 3 SVM models to refine prognosis of NPC with
5-year follow-up. The SVM1 displayed highly predictive sensitivity (sensitivity, specificity were 88.0% and 81.9%,
respectively) by integrating the expression of 7 molecular biomarkers. The SVM2 model showed highly predictive specificity
(sensitivity, specificity were 84.0% and 94.5%, respectively) by grouping the expression level of 12 molecular biomarkers and
3 EBV-related serological biomarkers. The SVM3 model, constructed by combination SVM1 with SVM2, displayed a high
predictive capacity (sensitivity, specificity were 88.0% and 90.3%, respectively). We found that 3 SVM models had strong
power in classification of prognosis. Moreover, Cox multivariate regression analysis confirmed these 3 SVM models were all
the significant independent prognostic model for overall survival in testing set and overall patients.
Conclusions/Significance: Our SVM prognostic models designed in the RCT displayed strong power in refining patient
prognosis for locally advanced NPC, potentially directing future target therapy against the related signaling pathways.
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Introduction
Nasopharyngeal carcinoma (NPC), an Epstein-Barr virus (EBV)
associated malignancy, has a remarkable racial and geographical
distribution in Southeast Asia [1,2]. Compared with the early stage
patients, cancer mortality associated with disease relapse still
sustained a high level in advanced NPC [3]. An accurate
identification of patient prognosis will benefit this subset for
developing distinct therapeutic and follow-up strategies in future.
Biomarker has been proven to be critical in predicting disease
prognosis by complimenting TNM classification for risk definition
[4]. More importantly, biomarkers, with dual functions for both
disease monitoring and novel molecular targeting, had shed the
light on personalized therapy. For example, overexpression of
EGFR, which occurred in 90% of head and neck squamous cell
carcinoma (HNSCC) [5], predicted an inferior patient outcome
[6]. EGFR monoclonal antibody Cetuximab had demonstrated a
survival benefit in combination with chemotherapy or radiother-
apy for HNSCC [2,7]. In recent BATTLE (Biomarker-Integrated
Approaches of Targeted Therapy for Lung Cancer Elimination)
study [8], the first large clinical trial to use tumor biomarkers to
guide therapy, 11 biomarkers associated with four NSCLC
molecular pathways were analyzed for directing treatment choice.
The results showed that each of the four treatments (erlotinib,
vandetanib, erlotinib plus bexarotene, and sorafenib) targeted
potently a specific molecular signature. Thus, identifying the
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the patient prognosis but also providing guidance for pathway
specific target therapy, will be of great benefit for advanced cancer
patients.
Data mining, including decision tree, neural networks (artificial
and fuzzy), and SVM, has been applied to predict cancer patient
prognosis [9,10,11]. Taken breast cancer and NSCLC for
example, SVM had been confirmed to be a strong tool to refine
the patient prognosis by integrating multi-gene profile [10,11]. In
head and neck cancer, the specific molecular pathway related
biomarkers signature had not yet been characterized using the
learning algorithms method based prognosis prediction model.
In the present study, we studied the expression levels of 38
markers, which represented 6 pathological signaling pathways,
and 3 EBV-related serological biomarkers associated with
tumorigenesis of NPC. We addressed the prognostic effect of
multi-biomarkers integrated SVM models with special focus on
whether SVM model could subgroup patient prognosis in head
and neck cancer.
Results
Immunohistochemical (IHC) Staining, Univariate and ROC
Curve Analysis
The baseline of patient clinicopathologic features of these two
cohorts were displayed in Table 1. The median follow-up period
was 63.8 months (range: 9.5 to 89.9 months) for overall patients.
As our previous report, the IC/RT and IC/CRT subgroups
displayed the similar OS (P=0.783). The median overall survival
was 73.9 and 70.1 months, respectively, in IC/RT and IC/CRT
subgroups. The 2-year and 5-year OS was respectively 84.1% and
73.8% in IC/RT subgroup, compared with 81.8% and 72.3% in
IC/CRT subset. The typical IHC staining of 38 biomarkers in
these NPC samples was shown in Figure 1. As revealed in Table 2,
each feature, that dichotomized by ROC curve generated cutoff
point (Figure 2A), was subjected to univariate analysis. In training
subgroup (48 patients), high tumor CENP-H (HR, 4.698;
P=0.023) and MMP 2 (HR, 3.489; P=0.039) expression were
associated with poor OS. In testing set, high Aurora-A (HR, 3.647;
P=0.021), Bcl-2 (marginal; HR, 4.423; P=0.052) and VCA-IgA
(HR, 3.787; P=0.017) levels predicted an inferior OS. For all
patients enrolled, high Aurora-A (HR, 2.872; P=0.010), MMP 2
(HR, 2.942; P=0.010) and VCA-IgA (HR, 2.688; P=0.014) levels
were correlated with worse OS. ROC curve analysis showed that
SVM models had the largest area under the curve (AUC)
compared with each individual AUC of 38 tissue molecules and
3 serological biomarkers (Figure 2), suggesting that SVM models
was the most powerful prognostic value in refining patient
outcome.
SVM1 and OS
The SVM1 model showed highly sensitivity by integrating the
expression levels of 7 tissue molecular biomarkers, including of
Aurora-A, Beclin 1, Ki-67, N-cadherin, nm23-H1, P27 and TIMP
2. After educating the model in the training set, we identified 19
patients with high risk to death and 30 patients with low risk at
testing set. The 5-year OS of the subgroup with high risk to death
was 38.9% compared with 89.5% in low risk subset (Figure 3A,
P,0.0001). Specifically, the predictive value of SVM1 in
sensitivity, specificity, positive predictive value, negative predictive
value, and overall accuracy were 78.6%, 77.1%, 57.9%, 90.0%
and 77.6%, respectively. Cox multivariate regression analysis
confirmed that SVM1 model was indeed the significant indepen-
dent predictive model for patient risk to death (Table 3; HR,
42.275; 95% CI, 2.474 to 722.425; P=0.010).
By summarizing the training and testing set as a group, we
identified 30 patients with high risk and 67 patients with low risk to
death. The 5-year OS of the patients with high risk to death was
24.1% compared with 95.3% in low risk subgroup (Figure 3A,
P,0.0001). Specifically, the predictive value of SVM1 in
sensitivity, specificity, positive predictive value, negative predictive
value, and overall accuracy were 88.0%, 81.9%, 62.9%, 95.2%
and 83.5%, respectively. Cox multivariate regression analysis
confirmed that SVM1 model was the significant independent
predictive model for patient risk to death (Table 3; HR, 320.826;
95% CI, 36.705 to 2804.256; P,0.0001). Moreover, a prognostic
effect on age, Aurora-A, Ki67 and P27 were also observed in
overall patients, though with relatively low HR (Table 3). The
clinical features, including of gender, TNM stage as well as
therapeutic regimens, and other molecular biomarkers however
failed to prove any prognostic value.
SVM2 and OS
The SVM2 model showed high specificity by grouping the
expression levels of 12 tissue molecular biomarkers (nm23-H1,
Pontin, cyclin D1, N-Cadherin, 14-3-3s, Ki-67, Aurora-A, Bcl-2,
Beclin 1, MMP 2, EZH2 and TIMP 2) and 3 EBV-related
serological biomarkers (EA-IgA, VCA-IgA and AER). After
educating the model in the training set, we identified 14 patients
with high risk to death and 35 patients with low risk at testing set
individually. The 5-year OS of the subset with high risk to death
was 28.6% compared with 87.8% in low risk subgroup (Figure 3B,
P,0.0001). In detail, the predictive value of SVM2 in sensitivity,
specificity, positive predictive value, negative predictive value, and
overall accuracy were 71.4%, 88.6%, 71.4%, 88.6% and 83.7%,
respectively. Cox multivariate regression analysis confirmed that
SVM2 model was indeed the significant independent predictive
model for patient risk to death (Table 3; HR, 6055.528; 95% CI,
2.718 to 1.349610
7; P=0.027).
By summarizing the training and testing set as a group, we
identified 25 patients with high risk and 72 patients with low risk to
death. The 5-year OS of the patients with high risk to death was
16.0% compared with 94.2% in low risk subgroup (Figure 3B,
P,0.0001). Specifically, the predictive value of SVM2 in
sensitivity, specificity, positive predictive value, negative predictive
value, and overall accuracy were 84.0%, 94.5%, 84.0%, 94.4%
and 91.8%, respectively. Cox multivariate regression analysis
confirmed that SVM2 model was the significant independent
predictive model for patient risk to death (Table 3; HR, 346.294;
95% CI, 24.742 to 4846.721; P,0.0001). In addition, Cyclin D1,
EA-IgA and VCA-IgA were also the independent prognostic
factors in overall patients, though with relatively low HR (Table 3).
SVM3 and OS
The SVM3 model, that incorporating SVM1 with SVM2, was
subjected to refine patient risk to death when risk definition
discrepancy was confronted at SVM1 and SVM2. In SVM3
model, we integrated the expression level of 13 tissue molecular
biomarkers (nm23-H1, Pontin, cyclin D1, N-Cadherin, 14-3-3s,
Ki-67, Aurora-A, Bcl-2, Beclin 1, MMP 2, EZH2, TIMP 2 and
P27) and 3 EBV-related serological biomarkers (EA-IgA, VCA-
IgA and AER). As shown in Figure 3C, we identified 13 patients
with high risk and 36 patients with low risk to death at testing set.
The 5-year OS of the subset with high risk to death was 30.8%
compared with 85.2% in low risk subgroup (Figure 3C,
P,0.0001). Specifically, the predictive value of SVM3 in
sensitivity, specificity, positive predictive value, negative predictive
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and 81.6%, respectively. Cox multivariate regression analysis
confirmed that SVM3 model was indeed the independent
predictive model for patient risk to death (Table 3; HR,
1401.433; 95% CI, 0.883 to 2.223610
6; P=0.054).
By summarizing the training and testing set as a group, we
identified 24 patients with high risk and 73 patients with low risk to
death. The 5-year OS of the patients with high risk to death was
16.7% compared with 92.8% in low risk subgroup (Figure 3C,
P,0.0001). Specifically, the predictive value of SVM3 in
sensitivity, specificity, positive predictive value, negative predictive
value, and overall accuracy were 88.0%, 90.3%, 75.9%, 95.6%
and 89.7%, respectively. Cox multivariate regression analysis
confirmed that SVM3 was an independent predictive model for
patient risk to death (Table 3; HR, 540.456; 95% CI, 33.336 to
8761.995; P,0.0001). Additionally, age, P27 and VCA-IgA
showed prognostic effect for overall patients, though with the
lower HR (Table 3).
Discussion
The important challenge complementing the anatomic TNM
staging prognostication is to integrate the nonanatomic molecular
biomarkers [12]. Indeed, circulating serological and tissue
molecular prognostic factors were currently used for predicting
cancer patient outcome individually. Here, we examined the
expression levels of 38 tissue molecular biomarkers representing 6
pathological signaling pathways and 3 EBV-related serological
biomarkers for further characterizing their prognostic value by
constructing the SVM models in a randomized controlled trial. By
integrating 16 biomarkers that displayed higher predictive values,
we designed 3 SVM prognosis models. Our finding demonstrated
that those 3 SVM models showed the powerful efficacy in defining
patient risk to death individually, indicating the promising clinical
usage in future therapeutic and follow-up management.
Accurate characterization of patient outcome, that not only
permits treatment to be individualized but also improves patient
follow-up economic benefit cost ratio, is markedly important for
locally advanced NPC. Biomarkers that aberrantly expressed in
tissue or circulation have been proven to be critical in guiding
treatment selection and predicting disease prognosis [4,12]. Both
the single biomarker reflecting the cancer phenotype in a
microscopical manner and the TNM stage system predicting
patient outcome in a macroscopical manner showed however a
limited predictive power for individual outcome. In the present
study, we designed a SVM model by integrating the expression
levels of several tissues molecular biomarkers and NPC specific
serological biomarkers to refine patient risk to death individually.
We thus raised three key clinical implications of this SVM based
prognostic model for locally advanced NPC: i) the molecular
biomarkers included in this study were detected by IHC and
ELISA and thus might be readily adaptable to clinical practice; ii)
patients with inconsistent definition of risk to death between
SVM1 and SVM2 models would be subjected to SVM3 for further
determination. iii) the therapeutic regimen for advanced NPC
might be redirected for the particular subgroup according to the
SVM risk definition. Specifically, the patients with low risk
definition could receive routine therapeutic regimen to avoid the
serious side effect of intensive treatment modality. However, for
patients with high risk definition, the standard chemoradiotherapy
might not be sufficient. The target agent that specific to the
particular molecular biomarker [13], and more aggressive
chemotherapy regimen may be employed to maximize the
therapeutic benefit.
In comparison with other data mining methods [14], such as
neural networks (artificial and fuzzy) [15], clustering [16], genetic
algorithms [17] and decision trees [18], SVM performs classifica-
tion by constructing an N-dimensional hyperplane that optimally
separates the data into two categories [19]. This feature thus
presented great priority in predicting cancer patients prognosis
that with two classifications (death VS alive). Additionally,
Newman-Keuls test was used to deal with multiple comparisons
that raised by multiple variables included in this study, ensuring
the rational IHC score for further SVM analysis. More
importantly, the higher generalization ability made SVM could
train the model with limited cases by grouping several efficient
features. Here, we designed the SVM models for advanced NPC
by integrating TNM stage, tissue molecular features (nm23-H1,
Pontin, cyclin D1, N-Cadherin, 14-3-3s, Ki-67, Aurora-A, Bcl-2,
Beclin 1, MMP 2, EZH2, TIMP 2, COX 2 and P27) along with
EBV-related biomarkers (AER, EA-IgA and VCA-IgA), which
reflected each patient tumorigenesis phenotype not only in
macroscopic but also in microcosmic aspect. Thus, these multi-
biomarkers based models would provide more powerful efficacy in
prediction of patient outcome. Indeed, our finding confirmed that
the SVM models had strong ability in refining patient risk to death
individually (Figure 3, high risk VS low risk: SVM1 24.1% VS
95.3%, SVM2 16.0% VS 94.2%, SVM3 16.7% VS 92.8%).
However, we also observed the inconsistence in predicting patient
outcome among SVMs in testing set regarding to age, Aurora-A,
P27 and VCA-IgA. Taken Aurora-A for example, P value were
0.608, 0.683 and 0.098 for SVM1, SVM2 and SVM3,
respectively. The underlying reasons might lie in the small cohort
size in testing set since the significant prognostic value was
observed when the cohort combined both training set and testing
subgroup.
Taken together, our study demonstrated that multibiomarkers
integrated SVM models led to more precise risk definition, offering
a promising and individualized selection for future therapeutic
regimen.
Methods
Patients
The 408 locally advanced NPC patients (Stage III and IVa)
were enrolled in a randomized controlled trial (RCT) designed for
therapeutic as well as SVM-biomarker study from August 2002 to
April 2005 [20]. In the therapeutic study, the therapeutic effect of
induction chemotherapy+radiotherapy (IC/RT) was compared to
induction chemotherapy+concurrent chemoradiotherapy (IC/
CRT). In this biomarker study, randomized 103 patients (50
IC/CRT+53 IC/RT) were selected for multi-biomarkers-SVM
prognosis analysis. Excluding 6 patients (4 IC/CRT+2 IC/RT)
lost to 5-year follow-up, 97 patients (46 IC/CRT+51 IC/RT) were
enrolled in this study. The baseline of patient clinicopathologic
features of these two cohorts were displayed in Table 1. Of these
97 patients, randomly selected 48 patients (25 IC/RT+23 IC/
CRT) were used as training set for SVM model education and the
rest of 49 patients (26 IC/RT+23 IC/CRT) served as testing set.
The cancer stage was defined according to the 1992 NPC staging
Figure 1. Immunohistochemical staining of tissue biomarkers in locally advanced NPC. The panel displayed the representative expression
of 37 molecular biomarkers in tumor zone for locally advanced NPC (original magnification, 6400).
doi:10.1371/journal.pone.0031989.g001
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PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e31989Figure 2. ROC curves plotted for patient outcome, using 38 tissue molecule expression scores, 3 serological biomarkers levels and
SVM models, in training set (A), testing set (B) and overall patients (C). In training set (A), at each immunohistochemical staining score of 38
tissue molecules and 3 serological biomarkers, the sensitivity and specificity for the outcome being studied were plotted, thus generating a ROC
curve. The score, that closest to the point with both maximum sensitivity and specificity (0.0, 1.0), was selected as the cutoff point for further analysis.
doi:10.1371/journal.pone.0031989.g002
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Ethics Review Board at Cancer Center of Sun Yat-sen University,
and written informed consent was obtained from all patients at
their recruitment.
Patient eligibility
In this RCT, strict eligibility criteria protocol was employed as
following: pathological confirmed as nonkeratinizing or undiffer-
entiated carcinoma of nasopharynx (World Health Organization
types of II or III); aged 18–65 years; performance status score: 0–2;
clinical stage: III-IVa; leukocyte count (WBC) $4.0610
9/L and
platelet $100.0610
9/L; total bilirubin (TBIL) and alanine
aminotransferase (ALT) ,26 the upper limit of normal value;
creatinine (Cr) ,1.56 the upper limit of normal value. Patients
were excluded from this RCT with the following exclusion criteria:
uncontrolled infection; previously received any anticancer therapy;
pregnancy and lactation; prior malignancy; unsuitable for
chemotherapy due to deficiency of liver, kidney, lung and heart.
The routine staging workup comprised of a detailed clinical
examination of the head and neck, fiberoptic nasopharyngoscopy,
magnetic resonance imaging (MRI) of the entire neck from the
base of the skull, chest radiography, abdominal sonography, a
complete blood count, and a biochemical profile. New Drug
Statistical Treatment 8.0 software was employed to generate a
random number table for further patient assignment.
Oncologic treatment
In IC/RT subset, patients received two cycle of floxuridine+-
carboplatin (floxuridine 750 mg/m
2, d1–5; carboplatin AUC=6)
chemotherapy and underwent radiotherapy thereafter at one week
interval. In IC/CRT subgroup, one week after completion of two
cycle floxuridine+carboplatin (floxuridine 750 mg/m
2, d1–5;
carboplatin AUC=6), patients received radiotherapy and con-
current carboplatin (AUC=6) chemotherapy on day 7, 28 and 49,
respectively.
Prior to and after the carboplatin infusion, 1000–1500 ml
normal saline, 20 g (250 ml) and normal saline 2000–3000 ml
were respectively given to patients. Aheading of drug infusion, the
5-hydroxytryptamine-3 receptor antagonists and dexamethasone
(20 mg) were used to guard against vomiting. For patients with
serious myelosuppression, the chemotherapy schedule would be
delayed to the serological leukocyte counts $3.0610
9/L and
platelet count $100.0610
9/L. The carboplatin dose adjustment
was based on the level of posttreatment creatinine clearance.
When posttreatment serological creatinine clearance $60 mL/
min, the original regimen could be maintained at the next cycle of
chemotherapy. When the creatinine clearance decreased to 40–
59 mL/min, a reduction of 50% carboplatin dose was required for
the next cycle of chemotherapy. Once the serum creatinine
clearance was less than 40 mL/min, carboplatin should be
removed at the next cycle of chemotherapy.
The traditional Co
60 c-ray or linear accelerator 6–8 MV photon
based two-dimensional technique was administered for radiother-
apy. The radiation fields were determined by the extension of the
tumor and local regional cervical lymph node invasiveness. The
target radiation fields, including the tumor and a 2-cm marginal
extension in all directions, obtained at least 90% of the mid-depth
central axis dose. During the first course, two lateral opposing
faciocervical portals were exposed to 36–40 Gy irradiation. At the
second course, facio-cervical splitting portals course was employed.
When the oropharynx was invaded, the facio-cervical portals
would be used in these 2 courses, followed by 8–12 Mev electric
beam irradiation at the posterocervical triangular regions. The
anterior nasal region (6–8 Gy) or the parapharyngeal region (6–
8 Gy) would be irradiated for subset with regional tumor invasion.
The accumulated radiation dose of 68–72 Gy, with 2 Gy daily
fractions and 5 days per week, was given to the primary tumor.
Additional boosted 8 to 12 Gy would be delivered to subgroup
with residual tumor and destructed skull base. The neck region
obtained 50 to 70 Gy radiation according to the extent of the
lymph node tumorigenic invasiveness. For lymph node negative
and positive invaded necks, 50 Gy and 60 to 70 Gy radiation
would respectively be given.
Immunohistochemical (IHC) staining and EBV-related
serological antibodies assay
Both tissue microassays and IHC were performed as previously
described [23,24]. The candidate biomarkers consisted of reported
prognostic markers with high predictive value and a number of key
tumorigenesis signaling pathways related molecules [12]. A total of
38 biomarkers (Figure 1) representing 6 pathological signaling
pathways related to NPC disease progression, consisting of cell
cycle: Cyclin D1 (Cell Signaling, #2978, 1:200 dilution), 14-3-3s
(Santa Cruz, SC-100638, 1:200 dilution), Aurora-A (Upstate,
1:200 dilution), CENP-H (Santa Cruz, SC-22792, 1:200 dilution),
Stathmin (Cell Signaling, #3352, 1:200 dilution), P21WAF1
(Santa Cruz, SC-817, 1:200 dilution), CDC2 (Santa Cruz, SC-53,
1:200 dilution), P27 (Millipore, clone Y236, 1:200 dilution), ERK
(Santa Cruz, SC-94, 1:200 dilution), p-ERK (Santa Cruz, SC-
7383, 1:100 dilution), Ki-67 (Santa Cruz, SC-23900, 1:50
dilution); migration & invasion: E-Cadherin (Cell Signaling,
#4065, 1:50 dilution), b-catenin (Millipore, MAB2081, 1:100
dilution), N-Cadherin (Upstate, clone 13A9, 1:200 dilution), Snail
(Abcam, ab70983, 1:50 dilution), Twist (Santa Cruz, SC-102032,
Table 1. Patient characteristics.
Variables Training set (n=48) Testing set (n=49)
Gender
Male 37 41
Female 11 8
Age (Year)
Mean $44.5 VS ,44.5
(Range)
23 VS 25 (24 to 64) 30 VS 19 (21 to 63)
T classification
T2 7 8
T3 22 24
T4 19 17
N classification
N0 4 3
N1 18 18
N2 21 19
N3 5 9
TNM stage
III 24 27
IV 24 22
Therapeutic regimen
IC/RT 25 26
IC/CRT 23 23
Abbreviation: IC/RT, Induction chemotherapy+radiotherapy; IC/CRT, Induction
chemotherapy+concurrent chemoradiotherapy.
doi:10.1371/journal.pone.0031989.t001
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Variables (.cutoff point
VS #cutoff point) Training set Testing set Overall patients
P value HR 95% CI P value HR 95% CI P value HR 95% CI
Aurora-A, .8.5 VS #8.5 0.208 2.146 0.654 to 7.042 0.021 3.647 1.220 to 10.903 0.010 2.872 1.289 to
6.400
Beclin 1, .5.0 VS #5.0 0.097 3.074 0.815 to 11.590 0.516 1.415 0.496 to 4.037 0.110 1.919 0.862 to
4.273
HIF-1a, .7.0 VS #7.0 0.771 1.193 0.364 to 3.911 0.219 1.987 0.665 to 5.940 0.239 1.607 0.729 to
3.543
Bcl-2, .5.0 VS #5.0 0.734 0.808 0.236 to 2.760 0.052 4.423 0.989 to 19.770 0.139 1.853 0.819 to
4.195
Bax, .3.5 VS #3.5 0.407 1.682 0.492 to 5.754 0.490 1.471 0.492 to 4.397 0.214 1.645 0.750 to
3.610
Snail, .3.5 VS #3.5 0.374 1.745 0.511 to 5.963 0.273 0.556 0.195 to 1.589 0.910 0.956 0.434 to
2.106
CENP-H, .5.0 VS #5.0 0.023 4.698 1.243 to 17.761 0.905 1.066 0.374 to 3.042 0.084 2.025 0.909 to
4.510
COX-2, .7.0 VS #7.0 0.562 1.421 0.433 to 4.664 0.101 2.499 0.837 to 7.463 0.097 1.954 0.886 to
4.306
Cyclin D1, .3.5 VS #3.5 0.726 1.236 0.377 to 4.052 0.249 1.864 0.646 to 5.378 0.254 1.579 0.720 to
3.463
Ki-67, .5.0 VS #5.0 0.622 1.348 0.411 to 4.417 0.671 0.795 0.276 to 2.292 0.995 1.003 0.457 to
2.197
C-Met, .3.5 VS #3.5 0.245 2.074 0.607 to 7.087 0.514 1.439 0.482 to 4.296 0.188 1.731 0.765 to
3.919
MMP 2, .8.5 VS #8.5 0.039 3.489 1.063 to 11.452 0.140 2.394 0.750 to 7.636 0.010 2.942 1.299 to
6.663
nm23-H1, .5.0 VS #5.0 0.653 1.313 0.401 to 4.307 0.665 1.260 0.442 to 3.595 0.560 1.263 0.576 to
2.768
P21WAF1, .3.5 VS #3.5 0.530 1.464 0.446 to 4.797 0.841 1.113 0.390 to 3.174 0.520 1.294 0.590 to
2.836
Stathmin, .7.0 VS #7.0 0.568 0.699 0.205 to 2.388 0.368 1.653 0.554 to 4.936 0.714 1.158 0.528 to
2.538
Survivin, .2.5 VS #2.5 0.599 1.375 0.419 to 4.509 0.884 0.925 0.324 to 2.638 0.757 1.132 0.516 to
2.481
TIMP 2, .8.5 VS #8.5 0.446 1.587 0.484 to 5.202 0.133 2.254 0.781 to 6.504 0.091 1.969 0.898 to
4.318
Twist, .2.5 VS #2.5 0.209 2.344 0.621 to 8.840 0.572 0.739 0.259 to 2.110 0.658 1.198 0.538 to
2.668
E-cadherin, .3.5 VS #3.5 0.616 1.355 0.413 to 4.442 0.525 0.709 0.246 to 2.045 0.894 0.948 0.433 to
2.079
N-cadherin, .3.5 VS #3.5 0.379 1.737 0.508 to 5.941 0.283 1.820 0.610 to 5.431 0.172 1.768 0.781 to
4.002
b-catenin, .5.0 VS #5.0 0.357 0.536 0.142 to 2.022 0.514 1.423 0.493 to 4.104 0.961 0.981 0.445 to
2.161
P27, .7.0 VS #7.0 0.277 1.977 0.578 to 6.754 0.159 2.196 0.735 to 6.557 0.073 2.109 0.932 to
4.773
CDC 2, .5.0 VS #5.0 0.297 1.880 0.573 to 6.166 0.662 0.792 0.278 to 2.259 0.637 1.208 0.551 to
2.648
EZH2, .10.5 VS #10.5 0.732 1.230 0.375 to 4.035 0.861 0.910 0.316 to 2.623 0.928 1.037 0.473 to
2.272
ERK, .5.0 VS #5.0 0.910 1.074 0.314 to 3.669 0.830 1.121 0.393 to 3.198 0.729 1.150 0.522 to
2.533
p-ERK, .2.5 VS #2.5 0.437 1.685 0.452 to 6.280 0.986 1.011 0.321 to 3.186 0.509 1.338 0.564 to
3.176
AKT1, .5.0 VS #5.0 0.314 0.491 0.123 to 1.964 0.820 0.881 0.296 to 2.622 0.467 0.732 0.316 to
1.695
Pontin, .3.5 VS #3.5 0.708 1.255 0.383 to 4.114 0.594 0.750 0.260 to 2.162 0.966 0.983 0.446 to
2.166
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PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e319891:50 dilution), c-Met (Santa Cruz, SC-161, 1:200 dilution), nm23-
H1 (Santa Cruz, SC-56928, 1:200 dilution); tumor microenviron-
ment: HIF-1a Millpore, MAB5382, 1:200 dilution), COX2 (Santa
Cruz, SC-58344, 1:200 dilution), MMP-2 (Santa Cruz, SC-53630,
1:200 dilution), MMP-9 (Santa Cruz, SC-6840, 1:200 dilution),
TIMP-2 (Santa Cruz, SC-21753, 1:200 dilution), VEGF (MaiXin,
1:200 dilution), CD31 (MaiXin, 1:200 dilution) microvessel density
(MVD), CD34 (MaiXin, 1:200 dilution) MVD, CD31
+/CD34
2
MVD, CD8 (MaiXin, 1:200 dilution), CD45RO (MaiXin, 1:200
dilution) and D2–40 (MaiXin, 1:200 dilution); apoptosis &
autophagy: Bax (Santa Cruz, SC-7480, 1:200 dilution), Bcl-2
(Santa Cruz, SC-7382, 1:50 dilution), Survivin (Santa Cruz, SC-
47750, 1:100 dilution), AKT 1 (Cell Signaling, #4685, 1:100
dilution), Pontin (Cell Signaling, #8959, 1:100 dilution), Beclin 1
(Santa Cruz, SC-11427, 1:200 dilution); epigenetic related
molecule EZH2 (Cell Signaling, #4905, 1:200 dilution) and
EBV related molecule LMP 1 (Santa Cruz, SC-57721, 1:200
dilution), were tested in this study. A negative control was utilized
by changing the specific primary antibody with non-immune
serum immunoglobulins at the 1:200 dilutions. Serological EBV
related antibodies, EA-IgA, VCA-IgA and anti-enzyme rate
(AER) of EBV DNase-specific neutralizing antibody, were tested
prior to oncologic treatment by ELISA method [25,26]. Anti-
body testing of each used antibody was done prior to the IHC
staining.
Semi-quantitative assessment of IHC
The expression profile of each biomarker was evaluated by
combined assessment of staining intensity and extent as we
previously described [13,24]. Immunohistochemical (IHC) stain-
ing was evaluated and scored by two independent pathologists
(X.-J.F. & J.X.) blindly to clinical follow-up data. The third
pathologist will arbitrate the discrepancy arose between these two
pathologists. Totally, the ratio of complete agreement of the
overall score reached to 87%. The MVD were evaluated by
counting CD31
+ capillaries, CD34
+ capillaries, CD31
+/CD34
2
capillaries and D2–40 (lymphangial specific marker) in the three
most vascularized areas (‘‘hotspots’’) [27,28]. The immune
microenvironment reactivity was assessed by counting positive
stained CD8 and CD45RO T cells in the three ‘‘hotspots’’ [29].
Table 2. Cont.
Variables (.cutoff point
VS #cutoff point) Training set Testing set Overall patients
P value HR 95% CI P value HR 95% CI P value HR 95% CI
MMP 9, .1.5 VS #1.5 0.707 0.777 0.209 to 2.896 0.201 0.482 0.157 to 1.475 0.248 0.606 0.259 to
1.418
14-3-3s, .7.0 VS #7.0 0.431 0.610 0.179 to 2.086 0.063 0.365 0.126 to 1.054 0.075 0.484 0.217 to
1.077
LMP 1, .5.0 VS #5.0 0.633 1.336 0.407 to 4.380 0.423 0.648 0.225 to 1.871 0.856 0.929 0.422 to
2.048
CD31MVD, .12249.6 VS
#12249.6
0.528 0.682 0.208 to 2.238 0.517 1.419 0.492 to 4.090 0.970 1.015 0.463 to
2.225
CD34MVD, .8803.7 VS
#8803.7
0.623 1.347 0.411 to 4.416 0.581 1.347 0.467 to 3.883 0.431 1.374 0.624 to
3.026
CD31
+/34
2MVD, .3155.9 VS
#3155.9
0.332 1.837 0.537 to 6.279 0.404 1.562 0.547 to 4.460 0.340 1.469 0.667 to
3.238
CD8, .62.5 VS #62.5 0.767 0.819 0.220 to 3.052 0.265 0.537 0.180 to 1.601 0.347 0.668 0.289 to
1.548
CD45RO, .82.5 VS #82.5 0.398 1.038 0.952 to 1.133 0.097 0.368 0.113 to 1.196 0.941 1.002 0.941 to
1.068
D 2–40, .95.1 VS #95.1 0.418 0.611 0.186 to 2.009 0.140 0.439 0.147 to 1.312 0.094 0.505 0.227 to
1.125
VEGF, .3.5 VS #3.5 0.129 0.281 0.054 to 1.450 0.554 1.432 0.437 to 4.693 0.469 0.709 0.280 to
1.797
EA-IgA, .1:40 VS #1:40 0.439 1.597 0.487 to 5.236 0.106 2.377 0.832 to 6.786 0.087 1.987 0.906 to
4.356
VCA-IgA, .1:320 VS #1:320 0.369 1.724 0.525 to 5.653 0.017 3.787 1.266 to 11.328 0.014 2.688 1.219 to
5.927
AER, .55.0% VS #55.0% 0.687 1.314 0.348 to 4.953 0.151 2/341 0.733 to 7.476 0.203 1.764 0.737 to
4.226
SVM1, 1VS 0 0.000 – – 0.001 8.593 2.388 to 30.923 0.000 27.969 8.313 to
94.098
SVM2, 1VS 0 0.000 – – 0.000 8.391 2.608 to 26.993 0.000 25.704 8.693 to
76.000
SVM3, 1VS 0 0.000 – – 0.001 6.566 2.187 to 19.719 0.000 20.187 7.473 to
54.531
Abbreviation: NPC, nasopharyngeal carcinoma; MMP, matrix metalloproteinase; TIMP, tissue inhibitors of metalloproteinases; LMP, latent membrane protein; MVD,
intratumoral microvessel density; VEGF, vascular endothelial growth factor; AER, anti-enzyme rate of EBV DNase-specific neutralizing antibody; SVM, support vector
machines.
doi:10.1371/journal.pone.0031989.t002
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PLoS ONE | www.plosone.org 8 March 2012 | Volume 7 | Issue 3 | e31989Figure 3. Kaplan-Meier estimated of overall survival (OS) for SVM1, SVM2 and SVM3 models identified high and low risk to death
subgroups in both testing set and overall patients. For SVM1 model (A), a significant survival disadvange was observed for the high risk to
death subgroup, which was identified by SVM1 model, in testing set (left panel) and overall patients (right panel). For SVM2 (B) and SVM3 model (C), a
statistically OS difference was shown between high and low risk to death subgroups, which was indentified respectively by SVM2 and SVM3 model, in
testing set (left panel) and overall patients (right panel).
doi:10.1371/journal.pone.0031989.g003
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expression
The receiver operating characteristic (ROC) curve analysis was
subjected to the selection of cutoff score in the training set as we
previously reported [24]. Briefly, the sensitivity and specificity for
patient outcome being studied at each score were plotted to
generate a ROC curve. The score localized closest to the point at
both maximum sensitivity and specificity, the point (0.0, 1.0) on
the curve, was selected as the cutoff score that might be correctly
classified patient outcome as death or alive.
Clinical outcome assessment
The patients in this RCT were all followed up with strict
protocol. After the completion of therapy, patients were observed
at 3-month intervals during the first 3 years and at 6-month
intervals thereafter. The latest date of each patient being followed
up was May 15 2010, ensuring the accurate 5-year survival
condition of each patient was obtained and readily for further
SVM analysis. The 5-year survival condition was defined as death
or alive at the appointed date of 5 years post-diagnosis. Overall
survival (OS) was defined as the time from diagnosis to the date of
death or censored at the latest date.
Sample size estimation
Given the robust capacity of SVM prognostication model in
optimally separating the data into two categories, a relative small
sample size might be enough to achieve the goal of powerful
prognosis prediction. In this study, the STATA COX regression
was used to estimate the sample size based on 38 biomarkers
expression level. In light of the 24.2% OS events probability in
therapeutic regimen RCT, a total of 95 cases were required to
achieve 90% power for a 5% significance level assuming the OS
HR increased .ten-fold for SVMs model. When considering the
subgroup that might loss to follow-up, the cases size was further
enlarged to 103.
Support vector machines (SVM) model construction
In this study, we considered the patient prognosis as a two-class
pattern classification (death VS alive). We employed a vector
X~ X1,X2,   Xn fg to denote the pattern of n components for a
patient. In our binary classification, patient who survived for more
than 5 years was denoted by {1 fg whereas z1 fg represented the
patient survived less than 5 years. The overall patients were
randomly divided into two subgroups: training set that was
employed to construct decision function D (N), and testing set was
used to test the predictive accuracy of decision function.
The main procedure for SVM classification involved two steps.
Firstly, the input feature vector X is mapped into a higher
dimensional space H through an underling nonlinear mapping
Qx ðÞ . Secondly, the linear classification is applied in this mapping
space. A SVM decision function D x ðÞcan be rewritten as
D(x)~vTQ(x)+b, where parameter v~ v1,v2,   vng f
denotes the support vector. The unknown parameter v could
be obtained through minimization of the following structural
risk function: J(v,x)~ 1
2vTvzC
P n
i~0
ji (1),
diD(xi)§1{ji,ji§0,i~1,2,...,n. The value of Cis a user-
specified positive parameter, and ji are slack variables. Given the
two classes are separable, minimizing the structural risk in (1)
contributes to the maximal separating margin between these two
classes.
In this study, the performance of classification was calculated
using the following loss function: Loss1 S1,S2 ðÞ ~
PS 1 ðÞ {PS 2 ðÞ jj z2 QS 1 ðÞ {QS 2 ðÞ jj , wherePS ðÞand QS ðÞde-
noted the overall accuracy and sensitivity for set S, respectively.
The definition of PS ðÞ and QS ðÞ was
PS ðÞ ~ number of correctly predicted samples in S=number of
 
total sample in SÞ (2), QS ðÞ ~ number of True Positive
 
in S=numberof TruePositiveznumber ofFalseNegative in SÞ.
To maximize the area under ROC curve, we also defined
another loss function based on ROC parameter as following:
Loss2 S1,S2 ðÞ ~ AS 1 ðÞ {AS 2 ðÞ jj (3), where AS ðÞindicated the
area under ROC curve for the testing set S.
The classical RBF kernel function kx ,y ðÞ ~exp { x{y jj 2= s ðÞ was
used in SVM model construction. To find optimal parameters of
SVM model, including kernel size s and regularization parameter
C, standard Leave-one-out cross-validation was employed to
search over a grid {10vlog2sv10,{10vlog2v10 ðÞ .
Statistical analysis
The multivariate Cox proportional hazards model was utilized
to estimate the hazard ratio (HR) and 95% confidence interval
(CI). The survival probabilities difference between patients subsets
in OS were determined by Kaplan-Meier analysis and log-rank
tests. A two-tailed P,0.05 was considered statistically significant.
Statistical analysis was performed using SPSS v. 17.0 (SPSS, Inc.,
Chicago, IL).
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